Abstract
Optimal vaccination and immunotherapy against coronavirus disease COVID-19 relies on the in-depth comprehension of immune responses determining the individual susceptibility to be infected by SARS-CoV-2 and to develop severe disease. We characterized the polarity and specificity of circulating SARS-CoV-2-specific T cell responses against whole virus lysates or 186 unique peptides derived from the SARS-CoV-2 or SARS-CoV-1 ORFeome on 296 cancer-bearing and 86 cancer-free individuals who were either from the pre-COVID-19 era (67 individuals) or contemporary COVID-19-free (237 individuals) or who developed COVID-19 (78 individuals) in 2020/21. The ratio between the prototypic T helper 1 (TH1) cytokine, interleukin-2, and the prototypic T helper 2 (TH2) cytokine, interleukin-5 (IL-5), released from SARS-CoV-2-specific memory T cells measured in early 2020, among SARS-CoV-2-negative persons, was associated with the susceptibility of these individuals to develop PCR-detectable SARS-CoV-2 infection in late 2020 or 2021. Of note, T cells from individuals who recovered after SARS-CoV-2 re-infection spontaneously produced elevated levels of IL-5 and secreted the immunosuppressive TH2 cytokine interleukin-10 in response to SARS-CoV-2 lysate, suggesting that TH2 responses to SARS-CoV-2 are inadequate. Moreover, individuals susceptible to SARS-CoV-2 infection exhibited a deficit in the TH1 peptide repertoire affecting the highly mutated receptor binding domain (RBD) amino acids (331-525) of the spike protein. Finally, current vaccines successfully triggered anti-RBD specific TH1 responses in 88% healthy subjects that were negative prior to immunization. These findings indicate that COVID-19 protection relies on TH1 cell immunity against SARS-CoV-2 S1-RBD which in turn likely drives the phylogenetic escape of the virus. The next generation of COVID-19 vaccines should elicit high-avidity TH1 (rather than TH2)-like T cell responses against the RBD domain of current and emerging viral variants.
Competing Interest Statement
L.Z. and G.K. are cofounders of everImmune, a biotech company devoted to the use of commensal microbes for the treatment of cancers. A.G., A.B.T. and A.M. as part of the Drug Development Department (DITEP) are Principal/sub-Investigator of Clinical Trials for Abbvie, Adaptimmune, Aduro Biotech, Agios Pharmaceuticals, Amgen, Argen-X Bvba, Arno Therapeutics, Astex Pharmaceuticals, Astra Zeneca, Astra Zeneca Ab, Aveo, Bayer Healthcare Ag, Bbb Technologies Bv, Beigene, Bioalliance Pharma, Biontech Ag, Blueprint Medicines, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Myers Squibb, Bristol-Myers Squibb International Corporation, Ca, Celgene Corporation, Cephalon, Chugai Pharmaceutical Co., Clovis Oncology, Cullinan-Apollo, Daiichi Sankyo, Debiopharm S.A., Eisai, Eisai Limited, Eli Lilly, Exelixis, Forma Tharapeutics, Gamamabs, Genentech, Gilead Sciences, Glaxosmithkline, Glenmark Pharmaceuticals, H3 Biomedicine, Hoffmann La Roche Ag, Incyte Corporation, Innate Pharma, Institut De Recherche Pierre Fabre, Iris Servier, Janssen Cilag, Janssen Research Foundation, Kura Oncology, Kyowa Kirin Pharm. Dev., Lilly France, Loxo Oncology, Lytix Biopharma As, Medimmune, Menarini Ricerche, Merck Kgaa, Merck Sharp & Dohme Chibret, Merrimack Pharmaceuticals, Merus, Millennium Pharmaceuticals, Molecular Partners Ag, Nanobiotix, Nektar Therapeutics, Nerviano Medical Sciences, Novartis Pharma, Octimet Oncology Nv, Oncoethix, Oncomed, Oncopeptides, Onyx Therapeutics, Orion Pharma, Oryzon Genomics, Ose Pharma, Pfizer, Pharma Mar, Philogen S.P.A., Pierre Fabre Medicament, Plexxikon, Rigontec Gmbh, Roche, Sanofi Aventis, Sierra Oncology, Sotio A.S, Syros Pharmaceuticals, Taiho Pharma, Tesaro, Tioma Therapeutics, Wyeth Pharmaceuticals France, Xencor, Y's Therapeutics, Research Grants from Astrazeneca, BMS, Boehringer Ingelheim, Janssen Cilag, Merck, Novartis, Pfizer, Roche, Sanofi. Non-financial support (drug supplied) from Astrazeneca, Bayer, BMS, Boringher Ingelheim, Johnson & Johnson, Lilly, Medimmune, Merck, NH TherAGuiX, Pfizer, Roche. N.L. reports to be a Speaker at Jazz Pharmaceutical. Lyon COVID study GROUP are Biomerieux employees or received grant from Biomérieux to perform experiments. F.S. reports consulting fees from Pfizer, BMS, MSD, Roche, Pierre Fabre Oncology, Leo Pharma, Bayer, Mylan/Viatris, Mundi Pharma, Vifor Pharma, Biogaran, Helsinn. D.D. reports consulting fees from Chugai and Roche. E.D. reports grants and personal fees from ROCHE GENENTECH, grants from SERVIER, grants from ASTRAZENECA, grants and personal fees from MERCK SERONO, grants from BMS, grants from MSD, grant and personal fees from Boehringer outside the submitted work. F.B. reports personal fees from Astra-Zeneca, Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Eli Lilly Oncology, Hoffmann-La Roche Ltd, Novartis, Merck, MSD, Pierre Fabre, Pfizer and Takeda, outside the submitted work. J-C.S. was a full-time employee of AstraZeneca between September 2017 and December 2019. J-C.S. reports consultancy: Relay Therapeutics, Gritstone Oncology and shares: Gritstone, AstraZeneca, Daiichi-Sankyo, outside the submitted work. G.G. is a member of the scientific board of Luxia Scientific and reports consultancy for Pileje and Luxia Scientific, outside the submitted work.
Clinical Trial
COVID-19 era: ONCOVID: NCT04341207 PROTECT-Cov: ANSM No: 2020-A01546-33 COVID-SER: NCT04341142 Pre-COVID-era: CALEX: RCB 2007 A01074-49 Dex2: NCT01159288 LUD 99 003: N-CSET: 99/090/752 IMAIL-2: EudraCT No:2007-001699-35.
Clinical Protocols
https://clinicaltrials.gov/ct2/show/NCT04341207
https://clinicaltrials.gov/ct2/show/NCT04341142
https://www.nature.com/articles/cddis201082
https://clinicaltrials.gov/ct2/show/NCT01159288
https://www.jimmunol.org/content/171/1/219
Funding Statement
L.D. has received support by the Philanthropia Fondation Gustave Roussy. The Gustave Roussy sponsored clinical study on COVID-19 (ONCOVID; NCT NCT04341207 has been supported by the Fondation Gustave Roussy, the Dassault family, Malakoff Humanis, Agnès b., Izipizi, andRalph Lauren. A-G.G. and I.L. were supported by Fondation pour la Recherche Médicale (FRM). Lyon COVID study GROUP are Biomerieux employees or received grant from Bioméireux to perform experiments. L.Z. and G.K. were supported by RHU Torino Lumière (ANR-16-RHUS-0008), ONCOBIOME H2020 network, the SEERAVE Foundation, the Ligue contre le Cancer (équipe labelisée); Agence Nationale de la Recherche - Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC); Cancéropôle Ile-de-France; FRM; a donation by Elior; the European Research Council (ERC); Fondation Carrefour; High-end Foreign Expert Program in China (GDW20171100085 and GDW20181100051), Institut National du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; LeDucq Foundation; the LabEx Immuno-Oncology; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); CARE network (directed by Prof. Mariette, Kremlin Biceêtre AP-HP), and the SIRIC Cancer Research and Personalized Medicine (CARPEM). G.I. and M.P. were supported by Italian Ministry of Health (grants Ricerca CorrenteLinea 1, 1 'Infezioni Emergenti e Riemergenti', projects COVID-2020-12371675 and COVID‐2020‐12371817). M.Mi and G.G. were supported by ANR Flash COVID-19 program and ARS-CoV-2 Program of the Faculty of Medicine from Sorbonne University ICOViD programs (PI: G.G.). M.Mer. is a member of the Gates Foundation's innate immunity advisory group and his work is supported by the Champalimaud Foundation through funds from grants UIDB/04443/2020, LISBOA-01-0145-FEDER-022231 and LISBOA-01-0246-FEDER-000007. Over the last 5 years: AM has been a Principal Investigator of Clinical Trials from the following companies: Roche/Genentech, BMS, Merck (MSD), Pfizer, Lytix pharma, Eisai, Astra Zeneca/Medimmune, Tesaro, Chugai, OSE immunotherapeutics, SOTIO, Molecular Partners, IMCheck, Pierre Fabre, Adlai Nortye. A.M. has been a Member of Clinical Trial Steering Committees for NCT02528357 (GSK), NCT03334617 (AZ) and a Member of Data Safety and Monitoring Board: NCT02423863 (Sponsor: Oncovir), NCT03818685 (Sponsor: Centre Léon Bérard). A.M. has been a compensated member of the following Scientific Advisory Boards: Merck Serono, eTheRNA, Lytix pharma, Kyowa Kirin Pharma, Novartis, BMS, Symphogen, Genmab, Amgen, Biothera, Nektar, Tesaro/GSK, Oncosec, Pfizer, Seattle Genetics, Astra Zeneca/Medimmune, Servier, Gritstone, Molecular Partners, Bayer, Partner Therapeutics, Sanofi, Pierre Fabre, RedX pharma, OSE Immunotherapeutics, Medicxi, HiFiBio, IMCheck, MSD, iTeos, Innate Pharma, Shattuck Labs, Medincell, Tessa Therapeutics, Deka Biosciences. A.M. has provided compensated Teaching/Speaker activities for Roche/Genentech, BMS, Merck (MSD), Merck Serono, Astra Zeneca/Medimmune, Amgen, Sanofi, Servier. AM has provided compensated Scientific & Medical Consulting for Roche, Pierre Fabre, Onxeo, EISAI, Bayer, Genticel, Rigontec, Daichii Sankyo, Imaxio, Sanofi/BioNTech, Molecular Partners, Pillar Partners, BPI, Faron, Applied Materials. AM has benefited of Non-Financial Support (travel expenses) from Astra Zeneca, BMS, Merck (MSD), Roche. A.M. is a shareholder of Pegascy SAS, Centessa Pharmaceuticals, HiFiBio, Shattuck Labs. A.M. has received pre-clinical and clinical research grants (Institutional Funding) from Merus, BMS, Boehringer Ingelheim, Transgene, Fondation MSD Avenir, Sanofi and Astra Zeneca. BLS has received founding from the French Government under the "Investments for the Future" programme managed by the National Agency for Research (ANR), Méditerranée-Infection 10-IAHU. E.D. reports grants and personal fees from ROCHE GENENTECH, grants from SERVIER, grants from ASTRAZENECA, grants and personal fees from MERCK SERONO, grants from BMS, grants from MSD, grant and personal fees from Boehringer and was supported by INCa 2018-1-PL BIO-06-1 outside the submitted work. J-P.S was supported by MSD Avenir and has received and personal fees from Roche, MSD, BMS, Lilly, AstraZeneca, Daiichi-Sankyo, Mylan, Novartis, Pfizer, PFO, LeoPharma and Gilead outside the submitted work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Oncovid: All patients provided written informed consent. Protocol approval was obtained from an independent ethics committee (ethics protocol number EudraCT No: 2020-001250-21). Gustave Roussy Data Protection Officer (DPO) has evaluated this project and sent to the principal investigator a formalized-operational action plan about data protection compliance: patient's information, security measures, good practices about pseudonymization, etc. All of the DPO's recommendations has been applied by the research team.In agreement with MR004 in France, we reported the series to the national information science and liberties commission. Ethic committees: The Agence Nationale de securite du medicament et des produits de sante (FRANCE) gave the approval for the clinical trial No. EudraCT 2020-001250-21 (reference: MEDAECPP-2020-03-0012). The Committee of the Convention for the Protection of Individuals CPP Ile de France XI (FRANCE) approved the clinical trail (reference: 20025-75647). Decision made: CPP Ile de France XI and Agence Nationale de securite du medicament et des produits de sante authorized Gustave Roussy (No. CSET 2020/3078) for the clinical trial ONCOVID (register as NCT04341207). PROTECT-Cov: All patients signed an informed consent for this study. The Committee of the Convention for the Protection of Individuals CPP Ouest6 (FRANCE) approved the clinical trail (reference: 20.05.20.77502). The Agence Nationale de securite du medicament et des produits de sante (FRANCE) gave the approval for the clinical trial (2020-A01546-33) COVID-SER: Written informed consent was obtained from all participants; ethics approval was obtained from the national review board for biomedical research in April 2020 (Comite de Protection des Personnes Sud Mediterranee I, Marseille, France; ID RCB 2020-A00932-37), and the study was registered on ClinicalTrials.gov (NCT04341142).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived CALEX: All patients signed an informed consent for this study. Informed consent was obtained, according to the Declaration of Helsinki, and the study was approved by the local ethics committee (Comite de Protection des Personnes (CPP) Hopital Bicetre - CALEX protocol, n ID RCB 2007-A01074-49, date 29 February 2008). Dex2: All patients signed an informed consent for this study. Protocol approval was obtained from the Kremlin Bicetre Hospital Ethics Committee (12 December 2005) and registered as NCT01159288. LUD 99 003: All patients signed an informed consent for this study. It was approved by the Protocol Review Committee of the Ludwig Institute for Cancer Research and by the ethics committee Commission d'Ethique Biomedicale Hospitalo-Facultaire de la Faculte de Medecine de l'Universite de Louvain (N-CSET: 99/090/752.). IMAIL-2: All patients signed an informed consent for this study. Protocol approval was obtained from the Kremlin Bicetre Hospital Ethics Committee (n 07-019) and the Agence Francaise de Securite Sanitaire des Produits de Sante (n A70385-27) in 2007, N EudraCT: 2007-001699-35. Blood from healthy donor: Buffy bags were purchased from l'Etablissement Francais du Sang (EFS), Paris (INSERM-EFS ethical permission no. 18/EFS/031)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available on request from the corresponding author LZ.
